文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

重症监护病房中的抗生素优化使用

Optimal antibiotic use in the intensive care unit.
PubMed 文献 · Crit Care · 2025-10-14
一句话结论ICU应常规采用多专科团队参与的抗生素优化策略,结合本地病原学、PK/PD优化、快速诊断与生物标志物,在确保及时恰当治疗的同时减少耐药产生。

本文综述ICU抗生素优化策略。耐药已成为影响ICU危重感染患者预后的最重要因素之一,全球耐药感染流行率上升凸显该问题对所有重症医生的紧迫性。优化策略包括熟悉本地ICU病原体及药敏、及时给药并优化PK/PD(理想剂量与输注时长)、微生物快速诊断指导降阶梯、使用降钙素原等生物标志物避免不必要用药并缩短疗程。ICU应常规设立正式抗生素管理项目,包括药师与微生物学家参与查房、专用医嘱套餐、计算机决策支持、医院感染预防方案及合理预防用药(含选择性消化道去污染)。多专科团队应常规实施并定期更新这些策略。

要点

  • 熟悉本地ICU病原体及其抗生素敏感性是优化ICU抗生素实践的首要环节。
  • 及时抗生素给药并结合PK/PD优化(理想剂量和输注时长)应作为所有ICU抗生素策略的关键组成部分。
  • 微生物快速诊断试验可确认目标病原体所需方案,并在可能时实现降阶梯治疗。
  • 降钙素原等生物标志物有助于避免ICU不必要抗生素使用并缩短总疗程。
  • ICU应常规设立正式抗生素管理项目,由重症、微生物、药学、感染病及感染控制多专科团队参与并定期更新。

适用人群与场景

  • ICU中发生危及生命的感染的患者。

处置流程与药物剂量

  • 熟悉本地ICU病原体及其抗生素敏感性。
  • 及时给予抗生素,并进行PK/PD优化,包括理想剂量和输注时长。
  • 采用微生物学检测,包括常规病原体鉴定和药敏试验,以及微生物快速诊断试验,以确认所需抗生素方案,并在可能时降阶梯治疗。
  • 使用降钙素原等生物标志物辅助避免不必要的抗生素使用并缩短总疗程。
  • ICU应常规采用正式项目审查和优化抗生素实践,可包括药师和微生物学家在ICU查房时提供针对性意见、使用专注于疗程(含停药)及剂量优化指导的专用医嘱套餐、计算机决策支持工具、纳入医院感染预防方案,以及合理使用抗生素预防方案(含选择性消化道去污染SDD)。
  • 在部分情况下可采用抗生素联合方案,以提高初始方案治疗成功的可能性,同时减少耐药产生的倾向。
  • 人工智能/机器学习方法未来将越来越多地用于增强抗生素决策。

研究设计与关键结果

  • 综述指出,抗生素耐药已成为影响ICU危及生命感染患者预后的最重要因素之一,全球耐药感染流行率上升凸显该问题对所有重症医生的重要性。
  • 抗生素使用应优化,以确保及时恰当治疗,同时尽量减少后续耐药产生。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ICU抗生素优化策略应由包括重症医生、微生物学家、药师、感染病专家和感染控制人员在内的多专科团队常规实施。
  • 作者认为,定期审查和更新ICU抗生素实践有助于保障其长期使用,以优化患者结局并尽量减少耐药产生。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Antibiotic resistance has emerged as one of the most important factors influencing the outcomes of patients with life-threatening infections in the ICU. The increasing prevalence of antibiotic-resistant infections globally highlights the importance of this issue for all intensivists.

MAIN BODY: Antibiotic utilization in the ICU should be optimized to ensure that timely appropriate treatment is administered in a way that minimizes the subsequent emergence of antibiotic resistance. Antibiotic strategies have been developed to assist clinicians in achieving this important balance. Familiarity with local ICU pathogens and their antibiotic susceptibilities is at the forefront of optimizing ICU antibiotic practices. Moreover, timely antibiotic administration along with pharmacokinetic/pharmacodynamic (PK/PD) optimization, including ideal dosing and infusion duration, should be key components of all ICU antibiotic strategies. Microbiologic testing to include conventional pathogen identification and susceptibility testing as well as use of microbiologic rapid diagnostic tests can confirm the antibiotic regimen that is required to treat the causative pathogens while allowing de-escalation to occur if possible. Similarly, biomarkers such as procalcitonin can aid with avoiding unnecessary antibiotic use in the ICU and shortening their overall duration. ICUs should routinely employ formal programs for reviewing and optimizing antibiotic practices. These programs can include directed input from pharmacists and microbiologists during ICU rounds, the use of specialized order sets focusing on duration of treatment with stop as well as dosing optimization guidance, use of computerized decision support tools, incorporated protocols for the prevention of nosocomial infections, and the appropriate use of antibiotic prophylaxis regimens to include selective digestive decontamination (SDD). Tracking antibiotic practices in the ICU, as well as changing patterns of pathogens and antibiotic susceptibilities, mandate regular modification and updating of these practices over time. Antibiotic combination regimens can also be employed in some circumstances to increase the likelihood of treatment success with an appropriate initial regimen while also reducing the propensity for resistance emergence. Additionally artificial intelligence/machine learning (AI/ML) methods will increasingly serve to enhance antibiotic decision making in the future.

CONCLUSION: Antibiotic optimization strategies in the ICU should routinely be employed by a multi-specialty group including intensivists, microbiologists, pharmacists, infectious disease specialists, and infection control practitioners. Regular review and updating of ICU antibiotic practices will help to safeguard their long-term use to optimize patient outcomes while minimizing resistance emergence.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Micek ST, Vazquez Guillamet MC, Reynolds D, et al. Optimal antibiotic use in the intensive care unit. Crit Care. 2025. PMID: 41088481. doi:10.1186/s13054-025-05653-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。